Literature DB >> 12208971

Inhibitory activity of synthetic peptide antibiotics on feline immunodeficiency virus infectivity in vitro.

Jia Ma1, Suzanne Kennedy-Stoskopf, Jesse M Jaynes, Linda M Thurmond, Wayne A Tompkins.   

Abstract

Natural peptide antibiotics are part of host innate immunity against a wide range of microbes, including some viruses. Synthetic peptides modeled after natural peptide antibiotics interfere with microbial membranes and are termed peptidyl membrane-interactive molecules (peptidyl-MIM [Demegen Inc, Pittsburgh, Pa.]). Sixteen peptidyl-MIM candidates were tested for activity against feline immunodeficiency virus (FIV) on infected CrFK cells. Three of them (D4E1, DC1, and D1D6) showed potent anti-FIV activity in chronically infected CrFK cells as measured by decreased reverse transcriptase (RT) activity, having 50% inhibitory concentrations of 0.46, 0.75, and 0.94 micro M, respectively, which were approximately 10 times lower than their direct cytotoxic concentrations. Treatment of chronically infected CrFK cells with 2 micro M D4E1 for 3 days completely reversed virus-induced cytopathic effect. Immunofluorescence revealed reduced p26 staining in these cells. Treatment of chronically infected CrFK cells with 2 micro M D4E1 suppressed virus production ( approximately 50%) for up to 7 days, The virions from the D4E1-treated culture had impaired infectivity, as measured by the 50% tissue culture infectious dose and nested PCR analysis of proviral DNA. However, these noninfectious virions were able to bind and internalize, suggesting a defect at some postentry step. After chronically infected CrFK cells were treated with D4E1 for 24 h, increased cell-associated mature p26 Gag and decreased extracellular virus-associated p26 Gag were observed by Western blot analysis, suggesting that virus assembly and/or release may be blocked by D4E1 treatment, whereas virus binding, penetration, RNA synthesis, and protein synthesis appear to be unaffected. Synthetic peptide antibiotics may be useful tools in the search for antiviral drugs having a wide therapeutic window for host cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12208971      PMCID: PMC136481          DOI: 10.1128/jvi.76.19.9952-9961.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Influence of amphipathic peptides on the HIV-1 production in persistently infected T lymphoma cells.

Authors:  M Wachinger; T Saermark; V Erfle
Journal:  FEBS Lett       Date:  1992-09-14       Impact factor: 4.124

2.  Antimicrobial defensin peptides form voltage-dependent ion-permeable channels in planar lipid bilayer membranes.

Authors:  B L Kagan; M E Selsted; T Ganz; R I Lehrer
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

3.  Interaction with phospholipid bilayers, ion channel formation, and antimicrobial activity of basic amphipathic alpha-helical model peptides of various chain lengths.

Authors:  Y Agawa; S Lee; S Ono; H Aoyagi; M Ohno; T Taniguchi; K Anzai; Y Kirino
Journal:  J Biol Chem       Date:  1991-10-25       Impact factor: 5.157

4.  A structural correlation between lentivirus transmembrane proteins and natural cytolytic peptides.

Authors:  M A Miller; R F Garry; J M Jaynes; R C Montelaro
Journal:  AIDS Res Hum Retroviruses       Date:  1991-06       Impact factor: 2.205

Review 5.  Early events in the immunopathogenesis of feline retrovirus infections.

Authors:  M B Tompkins; P D Nelson; R V English; C Novotney
Journal:  J Am Vet Med Assoc       Date:  1991-11-15       Impact factor: 1.936

6.  Direct virus inactivation of tachyplesin I and its isopeptides from horseshoe crab hemocytes.

Authors:  T Murakami; M Niwa; F Tokunaga; T Miyata; S Iwanaga
Journal:  Chemotherapy       Date:  1991       Impact factor: 2.544

7.  Myristoylation-dependent replication and assembly of human immunodeficiency virus 1.

Authors:  M Bryant; L Ratner
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

8.  Anti-human immunodeficiency virus activity of a novel synthetic peptide, T22 ([Tyr-5,12, Lys-7]polyphemusin II): a possible inhibitor of virus-cell fusion.

Authors:  H Nakashima; M Masuda; T Murakami; Y Koyanagi; A Matsumoto; N Fujii; N Yamamoto
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

9.  Lymphocyte population changes in cats naturally infected with feline immunodeficiency virus.

Authors:  C Novotney; R V English; J Housman; M G Davidson; M P Nasisse; C R Jeng; W C Davis; M B Tompkins
Journal:  AIDS       Date:  1990-12       Impact factor: 4.177

10.  A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition.

Authors:  C Wild; T Oas; C McDanal; D Bolognesi; T Matthews
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

View more
  4 in total

1.  Preferential feline immunodeficiency virus (FIV) infection of CD4+ CD25+ T-regulatory cells correlates both with surface expression of CXCR4 and activation of FIV long terminal repeat binding cellular transcriptional factors.

Authors:  Anjali Joshi; Himanshu Garg; Mary B Tompkins; Wayne A Tompkins
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

2.  The Influence of Short Motifs on the Anticancer Activity of HB43 Peptide.

Authors:  Claudia Herrera-León; Francisco Ramos-Martín; Hassan El Btaouri; Viviane Antonietti; Pascal Sonnet; Laurent Martiny; Fabrizia Zevolini; Chiara Falciani; Catherine Sarazin; Nicola D'Amelio
Journal:  Pharmaceutics       Date:  2022-05-19       Impact factor: 6.525

3.  Novel Therapeutic Approach for Inhibition of HIV-1 Using Cell-Penetrating Peptide and Bacterial Toxins.

Authors:  Steven Samuels; Zainab Alwan; Marceline Egnin; Jessie Jaynes; Terry D Connell; Gregory C Bernard; Toufic Nashar
Journal:  J AIDS Clin Res       Date:  2017-10-23

4.  Design and biological activities of novel inhibitory peptides for SARS-CoV spike protein and angiotensin-converting enzyme 2 interaction.

Authors:  Tin-Yun Ho; Shih-Lu Wu; Jaw-Chyun Chen; Yen-Chiao Wei; Shin-Ei Cheng; Yung-Hsien Chang; Hsu-Jan Liu; Chien-Yun Hsiang
Journal:  Antiviral Res       Date:  2005-11-28       Impact factor: 5.970

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.